|Articles|April 1, 1998

Clinical and Economic Considerations of Coronary Heart Disease: A Managed Care Approach
Volume 4
Issue 4 Suppl

Methods and Mindsets in Pharmacoeconomics

Author(s)William F. McGhan, PharmD, PhD

Download PDF: Methods and Mindsets in Pharmacoeconomics

Articles in this issue

over 28 years ago

Article

Participating Faculty

over 28 years ago

Article

Introduction: Clinical and Economic Considerations of Coronary Heart Disease: A Managed Care Approach

over 28 years ago

Article

Coronary Heart Disease in the United States

over 28 years ago

Article

Mechanisms of Acute Coronary Events

over 28 years ago

Article

Primary Prevention

over 28 years ago

Article

Pravastatin Event Reduction Analysis

over 28 years ago

Article

Secondary Prevention

over 28 years ago

Article

Point/Counterpoint: Is LDL-C Reduction the Outcome of Choice?

over 28 years ago

Article

Issues and Controversies in Pharmacoeconomics

over 28 years ago

Article

Pharmacoeconomics Perspectives: Payers, Providers, and Patients

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Blood Pressure Control Among Adherent vs Nonadherent Medicare Patients With Hypertension

ByKaitlyn T. Haas, PharmD,Joseph J. Saseen, PharmD, BCPS, BCACP,Oliver Titus, MS,Nathan Lamberton, PharmD, BCACP,Lisa M. Schilling, MD, MSPH,Keri N. Hogan, PharmD, BCACP,Alison Marks, BA,Sarah J. Billups, PharmD, BCPS

July 1st 2026

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

ByOnur Baser, PhD, MS,Heidi C. Waters, PhD,Nehir Yapar, BS,Gabriela Samayoa, MD, MPH,Xue Han, PhD,Deborah Freedman, MBA,Lauren Isenman, MPH,Rashmi Patel, MD, PhD

June 12th 2026

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

ByJason Bartock, MD,Adam Green, MD,Raquel Nahra, MD,Amy Bordogna, MD,Amir Davoodi, MD,Jean-Sebastien Rachoin, MD

June 11th 2026

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

Methods and Mindsets in Pharmacoeconomics

Articles in this issue

Related Content

Blood Pressure Control Among Adherent vs Nonadherent Medicare Patients With Hypertension

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Trending on AJMC

COVID-19 May Follow a Different Seasonal Pattern Than Influenza, RSV

Ocrelizumab Led to Declines in Immunoglobulins in Patients With MS

House Passes Bill to Ease Medicare ACO Digital Quality Reporting Burden

The Oncology Care Model: A Decade of Transformation

House Panel Advances Bills to Expand Veterans’ Health Care Access